Inventor · disambiguated record
Jiahua Jiang
Also filed as: JIANG JIAHUA
6 granted patents·8 pending applications·3 citations·filing 2017–2021
68Inventor score
Files withJIANGSU HENGRUI MEDICINE CO12SHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE LTD1SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD1
Top patents by PatentIndex Score
14 records- 0181US11359021B2PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Jun 14, 2022·2 cites·20 claims
- 0269US11525005B2Anti-CD40 antibody, antigen binding fragment thereof and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted Dec 13, 2022·1 cites·25 claims
- 0360US10857146B2Method for preventing or treating tumor diseases with a combination of tyrosine kinase inhibitor and CDK4/6 inhibitorJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Dec 8, 2020·0 cites·12 claims
- 0459US12227583B2Anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical useJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Feb 18, 2025·0 cites·17 claims
- 0553US2024010748A1Bispecific antibody for claudin 18a2 and cd3 and application of bispecific antibodySHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE LTD·Filed 2021·Application pending·0 cites
- 0648US2021009706A1Anti-CD27 Antibody, Antigen-binding Fragment Thereof, and Medical Use ThereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 0748US2024254248A1Cd40 antibody pharmaceutical composition and use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 0848US2022025060A1Anti-cd40 antibody, antigen binding fragmentand pharmaceutical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 0947US12162944B2Human IL-4R binding antibody, antigen binding fragment thereof, and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Granted Dec 10, 2024·0 cites·18 claims
- 1045US11000518B2Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancerJIANGSU HENGRUI MEDICINE CO·Filed 2017·Granted May 11, 2021·0 cites·5 claims
- 1144US2020054764A1Medical use of anti-c met antibody-cytotoxic drug conjugateSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2017·Application pending·0 cites
- 1244US2021363266A1Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 1342US2020131263A1Anti-gitr antibody, antigen-binding fragment thereof, and pharmaceutical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Application pending·0 cites
- 1440US2019225698A1Anti-cd27 antibody, antigen-binding fragment thereof, and medical use of sameJIANGSU HENGRUI MEDICINE CO·Filed 2017·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →